方达医药新闻资讯

Nicholas Pimlett 先生加入 Frontage Laboratories，担任联盟和项目管理副总裁。

在加入 Frontage 之前，Nicholas 在 SANOFI 拥有超过 18 年的工作经验，曾担任多个职位，职责越来越大。他以生物分析科学家的身份在实验室开始了他的职业生涯，在获得 MBA 学位后，他转向外包管理，以支持北美、欧洲和亚洲的研发项目。这种科学和运营经验使他有机会担任全球临床前部门和北美研发中心的参谋长。随后，他在美国担任合规和业务运营职位，随后扩展至监管全球医疗业务运营和合规组织，该组织负责管理 40 多个国家的财务法规和 85 个国家的合规法规。他最近的职位是在 TEMPUS LABS 担任联盟管理副总裁。

方达控股公布2020年中期业绩

自 2020 年 3 月以来，美国的 COVID-19 病例数持续上升，对本集团的业务造成负面影响。全球大流行限制了本集团员工提供实验室服务的全部能力，并降低了其交付效率。本集团已采取各种缓解措施，重点关注其员工、客户和合作伙伴的安全和福祉，以及业务运营的连续性，以尽量减少大流行的不利影响。本集团在美国的设施继续以较低的利用率运营。

Frontage announces the appointment of Dr. Yining Qi as Executive VP of Frontage Laboratories, Inc and President of Frontage Greater China.

Frontage is pleased to announce the appointment of Dr. Yining Qi as Executive VP of Frontage Laboratories, Inc. and President of Frontage Greater China. Dr. Qi has nearly 30 years of experience in research and development leadership and overseeing operations in the regulated pharmaceutical industry. In this role, Dr. Qi will be responsible for the overall leadership and strategic growth of Frontage Greater China operations.

Dr. Daniel Tang joins Frontage Laboratories, Inc. as Senior Vice President of Bioanalytical and Biologics Services.

Dr. Daniel Tang joins Frontage Laboratories, Inc. as Senior Vice President of Bioanalytical and Biologics Services.

ANVISA Certification

Brazil’s Agencia Nacional de Vigilancia Sanitaria (ANVISA) approved Frontage Laboratories to conduct bioanalytical services to support bioequivalence studies. ANVISA certified that Frontage Laboratories meets the agency’s stringent biopharmaceutical safety guidelines allowing the company to conduct bioanalytical work on its clients drug products.  The certification will be valid until August 2022. and has been published on ANVISA website (www.anvisa.gov.br.) 

Frontage expands synthetic & medicinal chemistry and process research & development services by acquisition of ACME Bioscience

ACME provides discovery chemistry, medicinal chemistry, process chemistry research & development, and chemical manufacturing services for worldwide biopharmaceutical companies.  ACME has extensive experience in antiviral and anti-bacterial research, along with expertise in nucleotides, nucleosides, triphosphates pro-drugs, heterocycles, and boron containing compounds, and has partnered with many customers in developing new chemical entities.

Frontage Laboratories, Inc establishes a QWBA Center of Excellence (COE) in Exton PA

Frontage Laboratories, a contract research organization (“CRO”) providing integrated, science-driven, product development services, has established a Quantitative Whole‑Body Autoradiography (QWBA) Center of Excellence (COE) at our Exton PA facility. 

Frontage develops a 3 in 1 multiplex PK assay for evaluation of hydroxy-chloroquine, chloroquine and azithromycin in human plasma to support COVID-19 clinical trials

In the battle against COVID-19, Frontage Bioanalytical, a contract research organization (“CRO”) providing integrated, science-driven, product development services, is first to announce development of potential cocktail PK assay for hydroxy-chloroquine, chloroquine and azithromycin in human plasma.